Search results for "Highlights"
No increase in mortality with incretin-based drugs compared to other diabetes meds, review finds
The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2017/07/14/3.htm
14 Jul 2017
Metformin appears to prevent type 2 diabetes, study indicates
Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
https://diabetes.acponline.org/archives/2017/08/11/2.htm
11 Aug 2017
New consensus statement on type 2 diabetes changes recommended drugs
The recommendations from the American Diabetes Association and the European Association for the Study of Diabetes encourage use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
https://diabetes.acponline.org/archives/2018/10/12/1.htm
12 Oct 2018
Spotlight on cognitive effects of diabetes
Two recent studies looked at the effects of diabetes on the brain, one focusing on mild cognitive impairment and the other on brain imaging findings.
https://diabetes.acponline.org/archives/2017/05/12/5.htm
12 May 2017
Weekly GLP-1 analogue associated with reduced MI, stroke risk, industry study finds
The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
https://diabetes.acponline.org/archives/2016/10/07/3.htm
7 Oct 2016
SGLT2 inhibitors may have class effect for reduction of cardiac risk
The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
https://diabetes.acponline.org/archives/2017/06/09/3.htm
9 Jun 2017
Spotlight on diabetes incidence and complications
Mortality and cardiovascular complications from diabetes have gone down, but incidence rates among youth are up, according to recent studies of Swedish and American patients, respectively.
https://diabetes.acponline.org/archives/2017/04/14/5.htm
14 Apr 2017
Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds
The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
https://diabetes.acponline.org/archives/2017/07/14/2.htm
14 Jul 2017
Screening tool identifies high-risk drivers with type 1 diabetes and website helps to avoid future accidents
Significant independent predictors of risk for driving mishaps included annual driving distance and presence of peripheral neuropathy. Researchers developed an 11-item questionnaire to further refine risk prediction.
https://diabetes.acponline.org/archives/2017/05/12/3.htm
12 May 2017
Behavioral intervention to increase physical activity led to lasting results at 3 years
At three outpatient diabetes clinics in Rome, Italy, participants who received specialized behavioral counseling sessions had greater increases in physical activity and decreases in sedentary time than those who received general physician recommendations.
https://diabetes.acponline.org/archives/2019/03/08/1.htm
8 Mar 2019